• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
LeadershipMartin Shkreli

Prosecutors Want Martin Shkreli to Forfeit His Wu Tang Clan CD

By
Reuters
Reuters
Down Arrow Button Icon
By
Reuters
Reuters
Down Arrow Button Icon
December 1, 2017, 12:51 PM ET

Martin Shkreli, dubbed the “pharma bro” for exploits such as jacking up the price of a life-saving drug by 5,000 percent, should forfeit $7.4 million, including his Wu Tang Clan album and a Picasso painting, U.S. prosecutors said on Friday.

The court should hold Shkreli financially accountable for his criminal conduct by requiring him to forfeit the amounts above, according to filings.

Prosecutors listed out assets that they can possibly take from Shkreli, also including his stake in Turing Pharmaceuticals and an Enigma machine, which was used in World War II as a code breaker.

Shkreli had bragged about buying the only copy of New York-based Wu Tang Clan’s “Once Upon a Time in Shaolin,” drawing ire from music fans around the world when he said he had no plans to listen to it.

In August, a U.S. jury convicted Shkreli of defrauding investors in hedge funds he ran years before he gained fame for hiking the price of a drug. His sentencing is scheduled for next month.

A U.S. judge ordered Shkreli to be jailed in September after a Facebook post offering a $5,000 reward for a strand of Hillary Clinton’s hair.

About the Author
By Reuters
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.